(Total Views: 159)
Posted On: 07/10/2025 7:32:33 PM
Post# of 96
OGM - Myth Busting 101
BIONANO GENOMICS (BNGO)
MYTH #1: “OGM is just for research.”
FACT: OGM is rapidly entering clinical workflows worldwide.
A new international expert panel just recommended OGM as a first-tier test for blood cancers.
OGM is now used in preimplantation genetic testing, helping families avoid passing on complex chromosomal disorders.
Johns Hopkins found OGM outperformed karyotyping and FISH in solid tumor diagnostics, and identified actionable variants in 98% of cases when paired with NGS.
MYTH #2: “Saphyr is outdated.”
FACT: Meet Stratys - the next-gen OGM system.
4x the throughput of Saphyr
12-sample random access chips (no batching!)
On-site AI-powered analysis with Stratys Compute
Already adopted in the U.S., Europe, Canada, and the Middle East
MYTH #3: “No path to reimbursement.”
FACT: Bionano now has two Category I CPT codes from the AMA.
One for hematologic malignancies
One for constitutional genetic disorders
These are permanent, billable codes, a major step toward routine clinical adoption
MYTH #4: “No global traction.”
FACT: OGM is going worldwide.
Featured at ESHG 2025 in Milan, Italy
Used in China for successful In Vitro Fertilization outcomes
Adopted by leading labs in Saudi Arabia, Germany, and Canada
CLIA labs in the U.S. are already offering OGM-based tests
OGM is not a fringe tool. It’s a scalable, clinically validated platform with global momentum, growing reimbursement, and next-gen tech in Stratys. The future of genomics isn’t coming, it’s already here.
BIONANO GENOMICS (BNGO)
MYTH #1: “OGM is just for research.”
FACT: OGM is rapidly entering clinical workflows worldwide.
A new international expert panel just recommended OGM as a first-tier test for blood cancers.
OGM is now used in preimplantation genetic testing, helping families avoid passing on complex chromosomal disorders.
Johns Hopkins found OGM outperformed karyotyping and FISH in solid tumor diagnostics, and identified actionable variants in 98% of cases when paired with NGS.
MYTH #2: “Saphyr is outdated.”
FACT: Meet Stratys - the next-gen OGM system.
4x the throughput of Saphyr
12-sample random access chips (no batching!)
On-site AI-powered analysis with Stratys Compute
Already adopted in the U.S., Europe, Canada, and the Middle East
MYTH #3: “No path to reimbursement.”
FACT: Bionano now has two Category I CPT codes from the AMA.
One for hematologic malignancies
One for constitutional genetic disorders
These are permanent, billable codes, a major step toward routine clinical adoption
MYTH #4: “No global traction.”
FACT: OGM is going worldwide.
Featured at ESHG 2025 in Milan, Italy
Used in China for successful In Vitro Fertilization outcomes
Adopted by leading labs in Saudi Arabia, Germany, and Canada
CLIA labs in the U.S. are already offering OGM-based tests
OGM is not a fringe tool. It’s a scalable, clinically validated platform with global momentum, growing reimbursement, and next-gen tech in Stratys. The future of genomics isn’t coming, it’s already here.
(0)
(0)
